Principaux différenciateurs
- Copolymère EVOH (éthylène-alcool vinylique) avec granulométrie micronisée de poudre de tantale
- Variété d'offres de viscosité : 12 cP, 18 cP et 34 cP
- Through the STEM Trial, the SquidTM liquid embolic agent demonstrated significant reduction in treatment failure with embolization and no increase in short-term adverse events in the treatment of cSDH compared to medical treatment alone
Indication d'utilisation
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness and requiring treatment in the opinion of the neurosurgical and neurointerventional team.
Vous souhaitez en savoir plus sur ce produit ?
Squid | Liquide embolique
